Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
CDK4/6 inhibition: PALOMA2 versus MONALEESA2

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.10.16
Views: 2588

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Dr Gnant talks to ecancertv at ESMO 2016 about the results of the MONALEESA-2 and PALOMA-2 trials, which confirm, he says, that the addition of cell cycle inhibitors (specifically, CDK4/6) can be of great benefit to patients with metastatic breast cancer.

He discusses the results of both trials with particular regards to toxicity.

MONALEESA-2 was discussed further by Dr Gabriel Hortobagyi here, and featured in the ecancer symposium on CDK4/6 inhibitors.

Supported by a grant from Pfizer Inc.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation